nach oben

Breast Cancer Research and Treatment

Erschienen in:

29.06.2020 | Letter to the Editor

A case for Tamoxifen with ovarian function suppression

verfasst von: Pallavi Kopparthy, Karen Daily

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Adjuvant endocrine treatment for premenopausal hormone receptor-positive breast cancer has become increasingly nuanced. Sufficient evidence and thus consensus exists on the treatment of patients at both ends of the spectrum; the lowest risk have excellent outcomes with Tamoxifen (TAM) alone for 5 years, and the highest risk have incremental benefit with the escalation of care to GnRHa-based ovarian function suppression (OFS) concurrent with chemotherapy followed by an Aromatase Inhibitor (AI). We describe clinical scenarios in which the third option, TAM with OFS, remains our preferred approach. …

Regan MM, Fleming GF, Walley B et al (2019) Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows. J Clin Oncol 37:862–866CrossRef

Pagani O, Francis PA, Fleming GF et al (2020) Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. J Clin Oncol 38:1293–1303CrossRef

Bellet M, Gray KP, Francis PA et al (2016) Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol 34:1584–1593CrossRef

Dignam JJ, Wieand K, Johnson KA et al (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467–1476CrossRef

Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28:3411–3415CrossRef

Titel: A case for Tamoxifen with ovarian function suppression
verfasst von: Pallavi Kopparthy
Karen Daily
Publikationsdatum: 29.06.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05766-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

A case for Tamoxifen with ovarian function suppression

Excerpt

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population

Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

Association between selenium intake and breast cancer risk: results from the Women’s Health Initiative

Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie